3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
2265
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1734
Leukemia
1500
Leukemia, Lymphocytic, Chronic, B-Cell
1120
Myelodysplastic Syndromes
963
Hematologic Neoplasms
935
Lymphoma
739
Lymphoma, Non-Hodgkin
654
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
532
Multiple Myeloma
501
Lymphoma, Follicular
467
Hodgkin Disease
460
Lymphoma, Mantle-Cell
459
Burkitt Lymphoma
440
Lymphoma, Large B-Cell, Diffuse
433
Lymphoma, B-Cell, Marginal Zone
402
Recurrence
356
Leukemia, Myelomonocytic, Chronic
351
Myeloproliferative Disorders
330
Leukemia, Myeloid, Chronic-Phase
311
Lymphoma, Large-Cell, Immunoblastic
303
Congenital Abnormalities
273
Neoplasms
271
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
249
Blast Crisis
246
Leukemia, Myeloid, Accelerated Phase
244
Primary Myelofibrosis
221
Neoplasms, Plasma Cell
220
Waldenstrom Macroglobulinemia
216
Lymphoma, T-Cell, Cutaneous
197
Interventions
nilotinib
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Substance Withdrawal Syndrome
×
Other hematologic neoplasm
×
Clear all
NCT04147533
2024-11-26
HALF
Masaryk University
Phase 2
Active not recruiting
150 enrolled
NCT03996096
2024-02-14
KIWIS
University Hospital, Caen
Completed
50 enrolled